The global artemisinin combination therapy market size is expected to reach USD 1.01 billion by 2030, registering a CAGR of 8.2% from 2024 to 2030. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
This product will be delivered within 1-3 business days.
Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.
Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.
WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.
Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.
Artemisinin Combination Therapy Market Report Highlights
- Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
- North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
- Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
- Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.
The leading players in the Artemisinin Combination Therapy market include:
- Novartis AG
- Sanofi S.A.
- Cipla Ltd.
- KPC Pharmaceuticals
- Fosun Pharmaceutical (Guilin Pharmaceutical)
- Ajanta Pharma
- Ipca Laboratories Ltd.
- Desano Inc.
- Hovid Berhad
- Mylan
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Artemisinin Combination Therapy Market Variables, Trends, & Scope
Chapter 4. Artemisinin Combination Therapy Market: Type Estimates & Trend Analysis
Chapter 5. Artemisinin Combination Therapy Market: Regional Estimates & Trend Analysis
Chapter 6. Competitive Landscape
Companies Mentioned
The leading players in the Artemisinin Combination Therapy market include:- Novartis AG
- Sanofi S.A.
- Cipla Ltd.
- KPC Pharmaceuticals
- Fosun Pharmaceutical (Guilin Pharmaceutical)
- Ajanta Pharma
- Ipca Laboratories Ltd.
- Desano Inc.
- Hovid Berhad
- Mylan
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 597.2 Million |
| Forecasted Market Value ( USD | $ 1010 Million |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
